Short-term treatment with rivastigmine and plasma levels of Ab peptides in Alzheimer’s disease

Journal Title: Folia Neuropathologica - Year 2005, Vol 43, Issue 4

Abstract

Deregulation of APP metabolism is considered to be a key pathogenic event in Alzheimer’s disease. Data from cell cultures indicate that the secretion of Ab1-42 might be inhibited by cholinesterase inhibitors, possibly via M1 receptors stimulation. Treatment with tacrine, a dual acetyl- and butyrylcholinesterase inhibitor, had no significant effect on mean plasma Ab species concentrations. However, a correlation was observed between higher drug concentrations and lower Ab levels that might indicate an effect on APP metabolism with an increased a-cleavage. Ab1-40 and Ab1-42 levels were measured in the plasma of 28 AD subjects by means of a commercially available ELISA before rivastigmine treatment and at week 2 after the first dose of the drug (3 mg/day) had been administered. Treatment with rivastigmine exhibited a significant effect on mean plasma concentrations of Ab1-42 (mean difference 7.8±8.4, t=-4.9, pmean difference 7.8±8.4, t=-4.9, p

Authors and Affiliations

Tomasz Sobow, Iwona Kloszewska

Keywords

Related Articles

Hemosiderin pigmentation of tumour cells in cerebellar pilocytic astrocytoma associated with post-traumatic hemorrhage in adults

The pilocytic astrocytoma is only rarely associated with gross intratumoral hemorrhage despite rich vasculature and blood vessel changes, accompanied often by perivascular depots of hemosiderin. We report an unusual cas...

No association between the brain-derived neurotrophic factor 196G>A or 270C>T polymorphisms and Alzheimer’s or Parkinson’s disease

The brain-derived neurotrophic factor (BDNF) promotes survival, differentiation and maintenance of neurons in the central nervous system. BDNF 196G>A and 270C>T polymorphisms have previously been associated with Alzheime...

Plaques and tangles and the pathogenesis of Alzheimer’s disease

Since the earliest descriptions, senile plaques (SP) and neurofibrillary tangles (NFT) have been regarded as the pathological hallmarks of Alzheimer’s disease (AD). Consequently, studies of the morphology, distribution...

Download PDF file
  • EP ID EP144326
  • DOI -
  • Views 85
  • Downloads 0

How To Cite

Tomasz Sobow, Iwona Kloszewska (2005). Short-term treatment with rivastigmine and plasma levels of Ab peptides in Alzheimer’s disease. Folia Neuropathologica, 43(4), 340-344. https://europub.co.uk./articles/-A-144326